VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?

The article favors Invesco S&P 500 Equal Weight Health Care ETF (RSPH) for long-term investors, citing 61 holdings versus VanEck Biotech ETF’s (BBH) 25 and lower five-year maximum drawdown of 21.9% versus 34.6%. Over the trailing year, BBH returned 38.3% versus RSPH’s 25.7%, while five-year growth of $1,000 was $1,284 for BBH and $1,315 for RSPH. RSPH has a 0.6% dividend yield and 0.40% expense ratio, compared with BBH’s 0.4% yield and 0.35% fee; the article views diversification as outweighing BBH’s modest cost advantage.

Analysis

The useful distinction is not simply concentration versus diversification: the funds embed different factor bets. BBH loads heavily on a few large drug developers, so a clinical, patent, or product-cycle disappointment at a top holding can dominate fund returns. RSPH reduces that single-name exposure, but equal weighting can give smaller or more volatile constituents more influence than a cap-weighted healthcare benchmark; its holdings still include biotech and diagnostics, so it is not a clean defensive hedge.

The recent relative performance gap is not sufficient evidence that the broader fund is the better forward trade. It may reflect a biotech rebound that could persist if trial results, launches, or deal activity improve; conversely, a reversal in biotech risk appetite would likely expose BBH’s concentration. The article provides no valuation, earnings-revision, flow, or current holdings data to establish which fund is mispriced. Its long-term diversification case is plausible, but should not be treated as a near-term catalyst.

For a 1–3 month decision, verify current holdings, NAV premiums/discounts, spreads, and relative fund flows before acting; no company-specific catalyst is established here. Over 6–18 months, monitor earnings revisions and pipeline outcomes among BBH’s largest positions, alongside breadth in devices, tools, and services. A relative allocation to RSPH is defensible for broad healthcare exposure, but the pair is a sector-composition trade, not a neutral hedge.

Key Decisions for Investors

• For a broad healthcare allocation, prefer RSPH over BBH as a measured relative-weighting decision—not as a claim that it will outperform in all regimes. Confirm live holdings and trading costs before entry.
• If biotech exposure is desired, keep BBH as a smaller satellite position rather than treating it as a diversified healthcare core; its top-holding concentration makes company-specific pipeline and patent news material to fund risk.
• A small long-RSPH/short-BBH pair is a possible way to express preference for broader healthcare breadth, but size it conservatively: biotech momentum or positive clinical catalysts could drive sharp underperformance in the short leg. Reassess if BBH’s earnings revisions and relative strength improve materially.
• Falsify the RSPH-over-BBH tilt if breadth in healthcare earnings deteriorates while biotech earnings revisions, pipeline outcomes, or relative fund flows strengthen; also pause until current NAV premiums/discounts and bid-ask spreads are checked.